Nitrous Oxide Emissions Generated in Coffee Cultivation: A Systematic Review

The objective of the research was to provide an overview of soil N2O emissions in coffee cropping systems; summarizing available field data on soil emissions and identifying controlling factors (fertilizer type, precipitation, temperature, altitude). A systematic search of Scopus, Science Direct, Springer, and Scielo for experimental-type studies was conducted from January 2000 to October 2021. Of the seventy manuscripts determined through the search strategy, eight studies met the inclusion criteria. Analysis of the included studies revealed that they were conducted in Ecuador, Costa Rica, and Nicaragua; the rainfall of the fields ranged from 910 mm to 2740 mm per year and the average temperature was 20.3°C. Coffee is planted under agroforestry systems and monocultures; in addition, the most abundant forest species in coffee agroforestry systems are leguminous plants of the Inga and Erytrina genus and 60% of the studies have been developed with the Catuai coffee variety. The pH and humidity of the soil where coffee plantations are developed range from 4.67 to 6.34 and 53.3 to 67.05% respectively. Finally, the fertilizers used are of chemical, organic, and chemical + polymer origin, at fertilization rates ranging from 66 to 400 kg.N.ha-1yr-1 and N2O emissions ranging from 0.2 to 12.8 kg.N.ha-1yr-1. Overall, the present systematic review provides a scientific basis for evaluating N2O emissions generated in coffee crops

Analysis of statistical knowledge of Peruvian medical students: a cross-sectional analytical study based on a survey

Introduction: Despite the growing awareness of the importance of knowledge in biostatistics, many investigations worldwide have found that medical students have a poor understanding of it. Objective: To determine the percentage of Peruvian medical students with sufficient biostatistics knowledge and the associated factors. Methods: Cross-sectional analytical study. Application of a virtual survey to medical students from different faculties in Peru. Results: 56.46% of medical students have insufficient knowledge of biostatistics. A statistically significant association was found for those who were 25 years of age or older (aPR: 1.195; 95% CI 1.045 - 1.366; p=0.009); being between the 9th and 12th semester (aPR: 1.177; 95% CI 1.001 - 1.378; p=0.037) and medical internship (aPR: 1.373; 95% CI 1.104 - 1.707; p=0.004); take an external course in biostatistics, epidemiology or research (aPR: 4.016; 95% CI 3.438 - 4.693; p<0.001); having read more than 12 articles per year (aPR: 1.590; 95% CI 1.313 - 1.967; p<0.001); and publish at least one scientific article (aPR: 1.549; 95% CI 1.321 - 1.816; p<0.001) or more than one (PR: 2.312; 95% CI 1.832 - 2.919; p<0.001). Conclusions: There is insufficient knowledge of biostatistics in medical students. The factors associated with a good understanding of this were age, academic semester, the number of articles read and published, and having taken an external course.Campus Lima Nort

Analysis of Statistical Knowledge of Peruvian Medical Students: A Cross-Sectional Analytical Study Based on a Survey

Introduction: Despite the growing awareness of the importance of knowledge in biostatistics, many investigations worldwide have found that medical students have a poor understanding of it. Objective: To determine the percentage of Peruvian medical students with sufficient biostatistics knowledge and the associated factors. Methods: Cross-sectional analytical study. Application of a virtual survey to medical students from different faculties in Peru. Results: 56.46% of medical students have insufficient knowledge of biostatistics. A statistically significant association was found for those who were 25 years of age or older (aPR: 1.195; 95% CI 1.045 - 1.366; p=0.009); being between the 9th and 12th semester (aPR: 1.177; 95% CI 1.001 - 1.378; p=0.037) and medical internship (aPR: 1.373; 95% CI 1.104 - 1.707; p=0.004); take an external course in biostatistics, epidemiology or research (aPR: 4.016; 95% CI 3.438 - 4.693; p&lt;0.001); having read more than 12 articles per year (aPR: 1.590; 95% CI 1.313 - 1.967; p&lt;0.001); and publish at least one scientific article (aPR: 1.549; 95% CI 1.321 - 1.816; p&lt;0.001) or more than one (PR: 2.312; 95% CI 1.832 - 2.919; p&lt;0.001). Conclusions: There is insufficient knowledge of biostatistics in medical students. The factors associated with a good understanding of this were age, academic semester, the number of articles read and published, and having taken an external course

Plan de negocio para el acopio y la comercializaci?n de palta variedad Hass (Persea americana Mil), por la empresa San Miguel Fruits Per? S.A. en el valle de Jequetepeque, Chep?n, La Libertad, Per?

El presente documento presenta una propuesta concreta de una l?nea marginal de negocio para la empresa San Miguel Fruits S.A. a nivel de una econom?a de escala, pero sin la adquisici?n de nuevas tierras, la cual consiste en el soporte t?cnico, acompa?amiento, acopio y la comercializaci?n de palta variedad Hass en el valle de Jequetepeque, Chep?n, La Libertad, Per?

Un examen actualizado de la percepción de las barreras para la implementación de la farmacogenómica y la utilidad de los pares fármaco/gen en América Latina y el Caribe

La farmacogenómica (PGx) se considera un campo emergente en los países en desarrollo. La investigación sobre PGx en la región de América Latina y el Caribe (ALC) sigue siendo escasa, con información limitada en algunas poblaciones. Por lo tanto, las extrapolaciones son complicadas, especialmente en poblaciones mixtas. En este trabajo, revisamos y analizamos el conocimiento farmacogenómico entre la comunidad científica y clínica de ALC y examinamos las barreras para la aplicación clínica. Realizamos una búsqueda de publicaciones y ensayos clínicos en este campo en todo el mundo y evaluamos la contribución de ALC. A continuación, realizamos una encuesta regional estructurada que evaluó una lista de 14 barreras potenciales para la aplicación clínica de biomarcadores en función de su importancia. Además, se analizó una lista emparejada de 54 genes/fármacos para determinar una asociación entre los biomarcadores y la respuesta a la medicina genómica. Esta encuesta se comparó con una encuesta anterior realizada en 2014 para evaluar el progreso en la región. Los resultados de la búsqueda indicaron que los países de América Latina y el Caribe han contribuido con el 3,44% del total de publicaciones y el 2,45% de los ensayos clínicos relacionados con PGx en todo el mundo hasta el momento. Un total de 106 profesionales de 17 países respondieron a la encuesta. Se identificaron seis grandes grupos de obstáculos. A pesar de los continuos esfuerzos de la región en la última década, la principal barrera para la implementación de PGx en ALC sigue siendo la misma, la "necesidad de directrices, procesos y protocolos para la aplicación clínica de la farmacogenética/farmacogenómica". Las cuestiones de coste-eficacia se consideran factores críticos en la región. Los puntos relacionados con la reticencia de los clínicos son actualmente menos relevantes. Según los resultados de la encuesta, los pares gen/fármaco mejor clasificados (96%-99%) y percibidos como importantes fueron CYP2D6/tamoxifeno, CYP3A5/tacrolimus, CYP2D6/opioides, DPYD/fluoropirimidinas, TMPT/tiopurinas, CYP2D6/antidepresivos tricíclicos, CYP2C19/antidepresivos tricíclicos, NUDT15/tiopurinas, CYP2B6/efavirenz y CYP2C19/clopidogrel. En conclusión, aunque la contribución global de los países de ALC sigue siendo baja en el campo del PGx, se ha observado una mejora relevante en la región. La percepción de la utilidad de las pruebas PGx en la comunidad biomédica ha cambiado drásticamente, aumentando la concienciación entre los médicos, lo que sugiere un futuro prometedor en las aplicaciones clínicas de PGx en ALC.Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations. Thus, extrapolations are complicated, especially in mixed populations. In this paper, we reviewed and analyzed pharmacogenomic knowledge among the LAC scientific and clinical community and examined barriers to clinical application. We performed a search for publications and clinical trials in the field worldwide and evaluated the contribution of LAC. Next, we conducted a regional structured survey that evaluated a list of 14 potential barriers to the clinical implementation of biomarkers based on their importance. In addition, a paired list of 54 genes/drugs was analyzed to determine an association between biomarkers and response to genomic medicine. This survey was compared to a previous survey performed in 2014 to assess progress in the region. The search results indicated that Latin American and Caribbean countries have contributed 3.44% of the total publications and 2.45% of the PGx-related clinical trials worldwide thus far. A total of 106 professionals from 17 countries answered the survey. Six major groups of barriers were identified. Despite the region’s continuous efforts in the last decade, the primary barrier to PGx implementation in LAC remains the same, the “need for guidelines, processes, and protocols for the clinical application of pharmacogenetics/pharmacogenomics”. Cost-effectiveness issues are considered critical factors in the region. Items related to the reluctance of clinicians are currently less relevant. Based on the survey results, the highest ranked (96%–99%) gene/drug pairs perceived as important were CYP2D6/tamoxifen, CYP3A5/tacrolimus, CYP2D6/opioids, DPYD/fluoropyrimidines, TMPT/thiopurines, CYP2D6/tricyclic antidepressants, CYP2C19/tricyclic antidepressants, NUDT15/thiopurines, CYP2B6/efavirenz, and CYP2C19/clopidogrel. In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC

An Updated Examination of the Perception of Barriers for Pharmacogenomics Implementation and the Usefulness of Drug/Gene Pairs in Latin America and the Caribbean

Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations. Thus, extrapolations are complicated, especially in mixed populations. In this paper, we reviewed and analyzed pharmacogenomic knowledge among the LAC scientific and clinical community and examined barriers to clinical application. We performed a search for publications and clinical trials in the field worldwide and evaluated the contribution of LAC. Next, we conducted a regional structured survey that evaluated a list of 14 potential barriers to the clinical implementation of biomarkers based on their importance. In addition, a paired list of 54 genes/drugs was analyzed to determine an association between biomarkers and response to genomic medicine. This survey was compared to a previous survey performed in 2014 to assess progress in the region. The search results indicated that Latin American and Caribbean countries have contributed 3.44% of the total publications and 2.45% of the PGx-related clinical trials worldwide thus far. A total of 106 professionals from 17 countries answered the survey. Six major groups of barriers were identified. Despite the region’s continuous efforts in the last decade, the primary barrier to PGx implementation in LAC remains the same, the “need for guidelines, processes, and protocols for the clinical application of pharmacogenetics/pharmacogenomics”. Cost-effectiveness issues are considered critical factors in the region. Items related to the reluctance of clinicians are currently less relevant. Based on the survey results, the highest ranked (96%–99%) gene/drug pairs perceived as important were CYP2D6/tamoxifen, CYP3A5/tacrolimus, CYP2D6/opioids, DPYD/fluoropyrimidines, TMPT/thiopurines, CYP2D6/tricyclic antidepressants, CYP2C19/tricyclic antidepressants, NUDT15/thiopurines, CYP2B6/efavirenz, and CYP2C19/clopidogrel. In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC

An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean

Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations. Thus, extrapolations are complicated, especially in mixed populations. In this paper, we reviewed and analyzed pharmacogenomic knowledge among the LAC scientific and clinical community and examined barriers to clinical application. We performed a search for publications and clinical trials in the field worldwide and evaluated the contribution of LAC. Next, we conducted a regional structured survey that evaluated a list of 14 potential barriers to the clinical implementation of biomarkers based on their importance. In addition, a paired list of 54 genes/drugs was analyzed to determine an association between biomarkers and response to genomic medicine. This survey was compared to a previous survey performed in 2014 to assess progress in the region. The search results indicated that Latin American and Caribbean countries have contributed 3.44% of the total publications and 2.45% of the PGx-related clinical trials worldwide thus far. A total of 106 professionals from 17 countries answered the survey. Six major groups of barriers were identified. Despite the region’s continuous efforts in the last decade, the primary barrier to PGx implementation in LAC remains the same, the “need for guidelines, processes, and protocols for the clinical application of pharmacogenetics/pharmacogenomics”. Cost-effectiveness issues are considered critical factors in the region. Items related to the reluctance of clinicians are currently less relevant. Based on the survey results, the highest ranked (96%–99%) gene/drug pairs perceived as important were CYP2D6/tamoxifen, CYP3A5/tacrolimus, CYP2D6/opioids, DPYD/fluoropyrimidines, TMPT/thiopurines, CYP2D6/tricyclic antidepressants, CYP2C19/tricyclic antidepressants, NUDT15/thiopurines, CYP2B6/efavirenz, and CYP2C19/clopidogrel. In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC